{"doc_id": "33181328", "type of study": "Therapy", "title": "", "abstract": "Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.\nTo evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia.\nA randomized, open-label controlled trial of oral favipiravir in adults hospitalized with moderate to severe COVID-19 pneumonia from June 22nd 2020 to August 13th 2020 was conducted.\nPatients were randomly assigned to receive either a combination of favipiravir with interferon beta-1b by inhalation aerosol or hydroxychloroquine (HCQ).\nThe outcome endpoints included improvement in inflammatory markers, lower length of hospital stay (LOS), discharges and lower overall 14-day mortality.\nA total of 89 patients underwent randomization with 49% (n = 44) assigned to favipiravir and 51% (n = 45) assigned HCQ.\nThe overall mean age was 55 \u00b1 14 years and 58% (n = 52) were males.\nThere were no significant differences in the inflammatory biomarkers at hospital discharge between the two groups; C-reactive protein (p = 0.413), ferritin (p = 0.968), lactate dehydrogenase (p = 0.259) and interleukin 6 (p = 0.410).\nThere were also no significant differences between the two groups with regards to the overall LOS (7 vs 7 days; p = 0.948), transfers to the ICU (18.2% vs 17.8%; p = 0.960), discharges (65.9% vs 68.9%; p = 0.764) and overall mortality (11.4% vs 13.3%; p = 0.778).\nNo differences in clinical outcomes were found between favipiravir plus inhaled interferon beta-1b and hydroxychloroquine in adults hospitalized with moderate to severe COVID-19 pneumonia.\nCopyright \u00a9 2020 The Authors.\nPublished by Elsevier Ltd.. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 121}, {"term": "moderate to severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 136, "end": 173}, {"term": "adult", "negation": "affirmed", "UMLS": {}, "start": 101, "end": 106}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 128}, {"term": "moderate to severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 171}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 85}, {"term": "moderate to severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 128}, {"term": "hospitalized", "negation": "negated", "UMLS": {}, "start": 132, "end": 144}, {"term": "moderate to severe COVID-19 pneumonia", "negation": "negated", "UMLS": {}, "start": 150, "end": 187}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 121}, {"term": "moderate to severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 136, "end": 173}], "Intervention": [{"term": "favipiravir combined with inhaled interferon beta-1b", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 105, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}, {"text": "interferon beta", "maps_to": "C0751599:interferon beta", "start": 34, "end": 49}], "has_relation": "combined_with (C1138226<->C0751599)"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia .", "Evidence Elements": {"Participant": [{"term": "adult", "negation": "affirmed", "UMLS": {}, "start": 101, "end": 106}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 128}, {"term": "moderate to severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 171}], "Intervention": [{"term": "favipiravir combined with inhaled interferon beta-1b", "negation": "affirmed", "UMLS": {}, "start": 45, "end": 97, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}, {"text": "interferon beta", "maps_to": "C0751599:interferon beta", "start": 34, "end": 49}], "has_relation": "combined_with (C1138226<->C0751599)"}], "Outcome": [{"term": "therapeutic effectiveness", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 41}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "A randomized , open-label controlled trial of oral favipiravir in adults hospitalized with moderate to severe COVID-19 pneumonia from June 22nd 2020 to August 13th 2020 was conducted .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 85}, {"term": "moderate to severe COVID-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 128}], "Intervention": [{"term": "oral favipiravir", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 62, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 5, "end": 16, "has_route": ["oral"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were randomly assigned to receive either a combination of favipiravir with interferon beta-1b by inhalation aerosol or hydroxychloroquine ( HCQ ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "combination of favipiravir with interferon beta-1b by inhalation aerosol or hydroxychloroquine (", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 148, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 15, "end": 26}, {"text": "interferon beta", "maps_to": "C0751599:interferon beta", "start": 32, "end": 47}, {"text": "inhalation", "maps_to": "C0354922:inhalations", "start": 54, "end": 64, "has_form": ["aerosol"]}, {"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 76, "end": 94}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The outcome endpoints included improvement in inflammatory markers , lower length of hospital stay ( LOS ) , discharges and lower overall 14-day mortality .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "inflammatory markers", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 66}, {"term": "length of hospital stay ( LOS )", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 106}, {"term": "discharges", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 119}], "Observation": [{"term": "improvement", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 42}, {"term": "lower", "negation": "affirmed", "UMLS": {}, "start": 69, "end": 74}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "lower", "Outcome": "", "Count": ""}]}, {"Section": "RESULTS", "Text": "A total of 89 patients underwent randomization with 49 % ( n = 44 ) assigned to favipiravir and 51 % ( n = 45 ) assigned HCQ .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 91, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The overall mean age was 55 \u00b1 14 years and 58 % ( n = 52 ) were males .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "There were no significant differences in the inflammatory biomarkers at hospital discharge between the two groups ; C-reactive protein ( p = 0.413 ) , ferritin ( p = 0.968 ) , lactate dehydrogenase ( p = 0.259 ) and interleukin 6 ( p = 0.410 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "between the two groups", "negation": "negated", "UMLS": {}, "start": 91, "end": 113, "has_relation": "N/A"}], "Outcome": [{"term": "inflammatory biomarkers at hospital discharge", "negation": "negated", "UMLS": {}, "start": 45, "end": 90}, {"term": "C-reactive protein", "negation": "negated", "UMLS": {}, "start": 116, "end": 134}, {"term": "ferritin", "negation": "negated", "UMLS": {}, "start": 151, "end": 159}, {"term": "lactate dehydrogenase", "negation": "negated", "UMLS": {}, "start": 176, "end": 197}], "Observation": [{"term": "significant differences", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 37}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "There were also no significant differences between the two groups with regards to the overall LOS ( 7 vs 7 days ; p = 0.948 ) , transfers to the ICU ( 18.2 % vs 17.8 % ; p = 0.960 ) , discharges ( 65.9 % vs 68.9 % ; p = 0.764 ) and overall mortality ( 11.4 % vs 13.3 % ; p = 0.778 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "two groups", "negation": "negated", "UMLS": {}, "start": 55, "end": 65, "has_relation": "N/A"}], "Outcome": [{"term": "overall LOS", "negation": "negated", "UMLS": {}, "start": 86, "end": 97}, {"term": "transfers to the ICU", "negation": "negated", "UMLS": {}, "start": 128, "end": 148}, {"term": "discharges", "negation": "negated", "UMLS": {}, "start": 184, "end": 194}], "Observation": [{"term": "significant differences", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 42}, {"term": "7", "negation": "negated", "UMLS": {}, "start": 100, "end": 101}, {"term": "7 days", "negation": "negated", "UMLS": {}, "start": 105, "end": 111}, {"term": "18.2 %", "negation": "affirmed", "UMLS": {}, "start": 151, "end": 157}, {"term": "17.8 %", "negation": "affirmed", "UMLS": {}, "start": 161, "end": 167}, {"term": "65.9 %", "negation": "affirmed", "UMLS": {}, "start": 197, "end": 203}, {"term": "68.9", "negation": "negated", "UMLS": {}, "start": 207, "end": 211}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "two groups", "has_relation": "N/A"}], "Observation": "significant differences", "Outcome": "overall LOS", "Count": ""}, {"Intervention": [{"term": "two groups", "has_relation": "N/A"}], "Observation": "significant differences", "Outcome": "transfers to the ICU", "Count": ""}, {"Intervention": [{"term": "two groups", "has_relation": "N/A"}], "Observation": "significant differences", "Outcome": "discharges", "Count": ""}, {"Intervention": {"term": "two groups", "has_relation": "N/A"}, "Observation": "7", "Outcome": "overall LOS", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "No differences in clinical outcomes were found between favipiravir plus inhaled interferon beta-1b and hydroxychloroquine in adults hospitalized with moderate to severe COVID-19 pneumonia .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "negated", "UMLS": {}, "start": 132, "end": 144}, {"term": "moderate to severe COVID-19 pneumonia", "negation": "negated", "UMLS": {}, "start": 150, "end": 187}], "Intervention": [{"term": "favipiravir plus inhaled interferon beta-1b", "negation": "negated", "UMLS": {}, "start": 55, "end": 98, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}, {"text": "interferon beta", "maps_to": "C0751599:interferon beta", "start": 25, "end": 40}], "has_relation": "combined_with (C1138226<->C0751599)"}, {"term": "hydroxychloroquine", "negation": "negated", "UMLS": {}, "start": 103, "end": 121, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [{"term": "clinical outcomes", "negation": "negated", "UMLS": {}, "start": 18, "end": 35}], "Observation": [{"term": "differences", "negation": "negated", "UMLS": {}, "start": 3, "end": 14}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "favipiravir plus inhaled interferon beta-1b", "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}, {"text": "interferon beta", "maps_to": "C0751599:interferon beta", "start": 25, "end": 40}], "has_relation": "combined_with (C1138226<->C0751599)"}, {"term": "hydroxychloroquine", "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}], "Observation": "differences", "Outcome": "clinical outcomes", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 The Authors .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier Ltd . . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}